In today’s briefing:
- Rainbow Children’s Hospital – Recent Updates and Peer Comp
- InnoCare Pharma Ltd (9969.HK) – Lack of Clear Commercialization Prospects
- Rainbow Children’s Hospital IPO – Thoughts on Valuation
Rainbow Children’s Hospital – Recent Updates and Peer Comp
- Rainbow Children’s Hospital (RCH) aims to raise around US$200m via issuing a mix of primary and secondary shares in its India IPO.
- RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.
- In this note, we will talk about the recent updates and peer comparison.
InnoCare Pharma Ltd (9969.HK) – Lack of Clear Commercialization Prospects
- InnoCare was approved to list in the SSE STAR Market, and the Company also released its improving financial performance in 2021. However, the outlook for InnoCare remains challenging and uncertain.
- Either orelabrutinib or the pipeline, they don’t have pricing power due to lack of sufficient competitiveness and slower development progress, which means that their commercialization performance is highly uncertain.
- There’s no definite commercialization outlook for InnoCare, with a far distance from becoming a biopharma. InnoCare was overvalued and could be attractive if the market value could be 50% off.
Rainbow Children’s Hospital IPO – Thoughts on Valuation
- Rainbow Children’s Hospital (RCH) aims to raise around US$200m via issuing a mix of primary and secondary shares in its India IPO.
- RCH is a multi-specialty pediatric and obstetrics and gynecology hospital chain in India, operating 14 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds.
- In this note, we will talk about our earnings forecast and thoughts on valuation.
Before it’s here, it’s on Smartkarma
